<DOC>
	<DOCNO>NCT02162719</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind study estimate efficacy , safety tolerability ipatasertib combine paclitaxel compare placebo combine paclitaxel participant inoperable locally advanced metastatic triple-negative breast cancer ( mTNBC ) , measure progression-free survival ( PFS ) participants participant phosphatase tensin homolog ( PTEN ) -low tumor .</brief_summary>
	<brief_title>A Study Assessing Safety Efficacy Adding Ipatasertib Paclitaxel Treatment Participants With Breast Cancer That Has Spread Beyond Initial Site , Cancer Does Not Have Certain Hormonal Receptors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically document triplenegative adenocarcinoma breast inoperable locally advanced metastatic amenable resection curative intent Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Availability representative formalinfixed , paraffinembedded ( FFPE ) tumor specimen , require prior randomization Measurable disease , accord RECIST v1.1 Adequate hematologic organ function within 14 day first study treatment For female participant childbearing potential , agreement ( participant partner ) use effective form contraception duration study 6 month last dose study treatment Any previous therapy , include chemotherapy hormonal target therapy , inoperable locally advanced metastatic triplenegative adenocarcinoma breast . Participants may receive prior neoadjuvant adjuvant chemotherapy and/or radiation treatment locally advanced triple negative adenocarcinoma , provide treatment complete great equal ( &gt; /= ) 6 month prior Cycle 1 Day 1 . Locally recurrent disease must amenable resection curative intent Any radiation treatment metastatic site within 28 day Cycle 1 , Day 1 Known Human Epidermal Growth Factor Receptor 2 ( HER2 ) positive , erythrocyte receptor ( ER ) positive , progesterone receptor ( PR ) positive breast cancer Previous therapy Akt , PI3K , and/or mTOR inhibitor Major surgical procedure , open biopsy , significant traumatic injury within 30 day prior Cycle 1 , Day 1 anticipation need major surgical procedure course study Known presence brain spinal cord metastasis , determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>